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BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor 
that reduces the risk of cardiovascular events. We report the effects on heart 
failure and cardiovascular death overall, in those with and without a baseline 
history of heart failure, and in other participant subgroups.
METHODS: The CANVAS Program (Canagliflozin Cardiovascular 
Assessment Study) enrolled 10 142 participants with type 2 diabetes 
mellitus and high cardiovascular risk. Participants were randomly assigned 
to canagliflozin or placebo and followed for a mean of 188 weeks. The 
primary end point for these analyses was adjudicated cardiovascular death 
or hospitalized heart failure.
RESULTS: Participants with a history of heart failure at baseline (14.4%) 
were more frequently women, white, and hypertensive and had a history 
of prior cardiovascular disease (all P<0.001). Greater proportions of these 
patients were using therapies such as blockers of the renin angiotensin 
aldosterone system, diuretics, and β-blockers at baseline (all P<0.001). Overall, 
cardiovascular death or hospitalized heart failure was reduced in those treated 
with canagliflozin compared with placebo (16.3 versus 20.8 per 1000 patient-
years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67–0.91), as 
was fatal or hospitalized heart failure (HR, 0.70; 95% CI, 0.55–0.89) and 
hospitalized heart failure alone (HR, 0.67; 95% CI, 0.52–0.87). The benefit on 
cardiovascular death or hospitalized heart failure may be greater in patients 
with a prior history of heart failure (HR, 0.61; 95% CI, 0.46–0.80) compared 
with those without heart failure at baseline (HR, 0.87; 95% CI, 0.72–1.06; 
P interaction =0.021). The effects of canagliflozin compared with placebo 
on other cardiovascular outcomes and key safety outcomes were similar in 
participants with and without heart failure at baseline (all interaction P values 
>0.130), except for a possibly reduced absolute rate of events attributable to 
osmotic diuresis among those with a prior history of heart failure (P=0.03).
CONCLUSIONS: In patients with type 2 diabetes mellitus and an 
elevated risk of cardiovascular disease, canagliflozin reduced the risk of 
cardiovascular death or hospitalized heart failure across a broad range 
of different patient subgroups. Benefits may be greater in those with a 
history of heart failure at baseline.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifiers: NCT01032629 and NCT01989754.
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Type 2 diabetes mellitus is associated with a substantial risk of cardiovascular and renal dis-ease, including heart failure.1–3 Heart failure in 
diabetes mellitus is attributed to macrovascular and 
microvascular dysfunction, volume overload, impaired 
renal function, and direct effects of diabetes mellitus 
and insulin resistance on cardiac myocytes.4–7 Mortal-
ity outcomes for patients with type 2 diabetes mel-
litus and heart failure are worse than for patients with 
either of the diseases alone, with a median survival 
of just 4 years.8 Before the introduction of sodium 
glucose cotransporter 2 (SGLT2) inhibitors, treatment 
with glucose-lowering agents has not been shown to 
reduce heart failure hospitalization,9 and there is evi-
dence of increased risks of heart failure in some trials 
of dipeptidyl peptidase-4 inhibitors10,11 and the thia-
zolidinedione class.9 Two landmark clinical trials using 
inhibitors of SGLT2—EMPA-REG OUTCOME12 and the 
CANVAS Program (Canagliflozin Cardiovascular As-
sessment Study)13—have demonstrated reductions in 
the risk of hospitalization for heart failure, with ben-
efits of empagliflozin reported across a broad range of 
patient groups.14 The present analyses explored in fur-
ther detail the effects of canagliflozin on heart failure 
and determined the effects of canagliflozin on a range 
of efficacy and safety outcomes among CANVAS Pro-
gram participants with and without a history of heart 
failure at baseline.
METHODS
Program Design
The study design, characteristics of participants, and main results 
of the CANVAS Program have previously been published.13,15 
In brief, the CANVAS Program, comprising the 2 similarly 
designed and conducted trials, CANVAS and CANVAS-R 
(CANVAS-Renal), was designed to assess the cardiovascular 
and renal safety and efficacy of canagliflozin compared with 
placebo, and also assess how any potential benefits might 
balance against risks. In total, 667 centers in 30 countries 
were involved in the 2 trials that were scheduled for joint 
closeout and analysis when ≥688 cardiovascular events and 
≥78 weeks of follow-up had been accrued for the last ran-
domized participant, which occurred in February 2017. A 
complete list of investigators and committees in the CANVAS 
Program is provided in the Appendix in the online-only Data 
Supplement. Data from the CANVAS Program will be made 
available in the public domain via the Yale University Open 
Data Access Project (http://yoda.yale.edu/) once the product 
and relevant indication studied have been approved by regu-
lators in the United States and European Union and the study 
has been completed for 18 months. The trial protocols and 
statistical analysis plans were published along with the pri-
mary CANVAS Program article.13
Participants
Participants included in the CANVAS Program were men 
and women with type 2 diabetes mellitus (glycohemoglo-
bin ≥7.0% and ≤10.5% and estimated glomerular filtration 
rate >30 mL/min/1.73 m2). Participants were also required 
to be either ≥30 years of age with a history of symptom-
atic atherosclerotic cardiovascular disease or ≥50 years of 
age with ≥2 risk factors for cardiovascular disease (duration 
of diabetes mellitus ≥10 years, systolic blood pressure >140 
mm Hg while on ≥1 antihypertensive agents, current smoker, 
documented microalbuminuria or macroalbuminuria, or doc-
umented high-density lipoprotein cholesterol <1 mmol/L). 
Patients with New York Association Class IV heart failure 
were excluded. The definition of heart failure at baseline was 
based on physician review of the patient’s medical history at 
the first visit, with no requirement for collection of diagnostic 
biomarkers or the conduct of echocardiography. All partici-
pants provided informed consent, and ethics approval was 
obtained for every center.
Randomization, Treatment, and 
Follow-up
After a 2-week, single-blind, placebo run-in period, partici-
pants were randomized centrally through an interactive web 
response system using a computer-generated randomization 
schedule prepared by the study sponsor using randomly per-
muted blocks. Participants in CANVAS were assigned in a 
1:1:1 ratio to canagliflozin 300 mg, canagliflozin 100 mg, 
or matching placebo, and participants in CANVAS-R were 
randomly assigned in a 1:1 ratio to canagliflozin or matching 
placebo, administered at an initial dose of 100 mg daily with 
optional uptitration to 300 mg from week 13. Participants 
and all study and sponsor staff were masked to individual 
treatment allocations until the completion of the study. Use 
of other background therapy for glycemic management, 
treatment of heart failure, and other risk factor control 
was according to best practices instituted in line with local 
guidelines.
Clinical Perspective
What Is New?
• The sodium glucose cotransporter 2 inhibitor cana-
gliflozin reduced the risk of a range of composite 
and cause-specific heart failure outcomes.
• Benefits from canagliflozin may be greater in those 
with a history of heart failure.
• There was no evidence that patients with a history 
of heart failure were likely to suffer higher rates of 
adverse events from canagliflozin.
What Are the Clinical Implications?
• Patients with type 2 diabetes mellitus at risk of 
heart failure are particularly likely to benefit from 
treatment with canagliflozin.
• Beneficial effects of canagliflozin on heart failure 
outcomes are likely to be accrued on top of other 
therapies for heart failure management.
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Participants were followed after randomization in a face-
to-face follow-up that was scheduled for 3 visits in the first 
year and at 6-month intervals thereafter, with alternating 
telephone follow-up between face-to-face assessments. Every 
follow-up included inquiry about primary and secondary out-
come events and serious adverse events. Serum creatinine 
measurement with estimated glomerular filtration rate was 
performed at least every 26 weeks in both trials. Participants 
who prematurely discontinued study treatment continued 
scheduled follow-up wherever possible, with extensive efforts 
made to obtain full outcome data for all participants during 
the final follow-up window that spanned from November 
2016 to February 2017.
Outcomes
The primary outcome for these analyses was the compos-
ite of cardiovascular death or hospitalized heart failure. 
The detailed criteria used to define outcomes are included 
in the Appendix in the online-only Data Supplement. 
Cardiovascular death included death resulting from an acute 
myocardial infarction, sudden cardiac death, death because 
of heart failure, death because of stroke, and death because 
of other cardiovascular causes. Hospitalized heart failure 
was an event that required an admission to an inpatient 
unit or a visit to an emergency department, resulting in a 
≥24-hour stay and ≥1 clinical symptoms of worsening heart 
failure, ≥2 physical signs of heart failure and a need for addi-
tional or increased therapy, and the absence of other non-
cardiac etiology or other cardiac etiology that might explain 
the presentation.
Secondary outcomes were fatal or hospitalized heart 
failure, fatal heart failure, hospitalized heart failure, the 
composite of major adverse cardiovascular events (cardio-
vascular death, nonfatal myocardial infarction, and non-
fatal stroke), fatal or nonfatal myocardial infarction, fatal 
or nonfatal stroke, all-cause mortality, and serious decline 
in kidney function (defined as a composite of 40% reduc-
tion in estimated glomerular filtration rate sustained for 
≥2 consecutive measures, the need for renal replacement 
therapy, or death from renal causes). The safety outcomes 
assessed were all serious adverse events and all adverse 
events leading to discontinuation, as well as amputation, 
fracture, osmotic diuresis–related adverse events (according 
to the Medical Dictionary for Regulatory Activities preferred 
terms: increase in urine output such as polyuria, pollakiuria, 
micturition urgency and nocturia, as well as those related 
to thirst; polydipsia, dry mouth, throat dry, or tongue dry), 
and volume depletion–related adverse events. End point 
adjudication committees adjudicated all cardiovascular out-
comes, renal outcomes, deaths, and fractures. Fatal heart 
failure events were those with heart failure adjudicated as 
the proximate cause of death.
Statistical Analysis
Categorical variables were summarized as the number of 
patients with corresponding percentages, and continu-
ous variables were summarized as the mean and standard 
deviation. Differences in baseline characteristics between 
participants with a history of heart failure compared with 
participants with no history of heart failure were evalu-
ated using a χ2 test for categorical variables, a t test for 
continuous normally distributed variables, and a Wilcoxon 
 2-sample test for continuous variables with a skewed dis-
tribution (distributions were evaluated using an Anderson–
Darling test).
Efficacy analyses were based on the full integrated data-
set and the intent-to-treat approach, with the comparison 
being between all participants assigned to canagliflozin 
(regardless of dose) and all participants assigned to pla-
cebo. Annualized incidence rates per 1000 patient-years 
of follow-up were calculated for all outcomes in addition 
to hazard ratios (HRs) and 95% confidence intervals (CIs) 
determined from Cox regression models that included a 
trial stratification factor. Absolute risk differences for 1000 
patients over 5 years and corresponding 95% CIs were esti-
mated as the differences in the incidence rates between 
randomized treatment groups using a Poisson regression 
analysis with an assumption of constant annual event prob-
abilities.16 On-treatment analysis (based on patients who 
experienced a safety outcome while on study drug or in ≤30 
days of study drug discontinuation) was used for the safety 
outcomes, except for amputation and fracture, which were 
assessed using intent-to-treat analyses. For all outcome 
analyses, we tested the homogeneity of treatment effects 
across the 2 contributing trials using P values for interac-
tions based on the joint test in the Cox regression models, 
and the same approach was used for testing comparability 
of effects across subgroups defined by baseline participant 
characteristics. There was no formal statistical adjustment 
for multiple comparisons, and P values were interpreted 
in light of the many assessments made. Analysis of recur-
rent hospitalization for heart failure was assessed with an 
Andersen‒Gill model. Analyses were performed using SAS 
version 9.2, SAS Enterprise Guide version 7.1, and STATA 
version 13.1.
RESULTS
There were 10 142 patients with type 2 diabetes mel-
litus in the CANVAS Program, and the mean follow-
up time was 188.2 weeks. Mean age was 63.3 years, 
35.8% of participants were women, the mean dura-
tion of diabetes mellitus was 13.5 years, and 65.6% 
had a history of cardiovascular disease. In addition, 
1461 (14.4%) participants reported a history of heart 
failure at baseline. These participants were significant-
ly different from the remaining participants in most 
aspects of demographics and disease history, in addi-
tion to exhibiting greater use of concomitant therapies 
used for the management of heart failure, including 
diuretics, renin angiotensin aldosterone system block-
ers, and β-blockers, but lower usage of statins and 
metformin (all P<0.001; Table). There were 203 car-
diovascular deaths or hospitalized heart failure events 
recorded among those participants who reported a 
history of heart failure at baseline and 449 among 
those who did not.
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Table. Baseline Characteristics of Participants With and Without Heart Failure at Baseline
Variable
Participants With Heart Failure Participants Without Heart Failure P Value 
Heart Failure 
vs No Heart 
Failure
Canagliflozin
(n=803)
Placebo
(n=658)
Total
(n=1461)
Canagliflozin
(n=4992)
Placebo
(n=3689)
Total
(n=8681)
Age, y, mean (SD) 64.1 (8.3) 63.4 (8.3) 63.8 (8.3) 63.1 (8.3) 63.5 (8.2) 63.2 (8.2) 0.025
Female, n (%) 346 (43.1) 302 (45.9) 648 (44.4) 1690 (33.9) 1295 (35.1) 2985 (34.4) <0.001
Race, n (%)       <0.001
  White 741 (92.3) 601 (91.3) 1342 (91.9) 3767 (75.5) 2835 (76.9) 6602 (76.1)  
  Asian 19 (2.4) 24 (3.6) 43 (2.9) 758 (15.2) 483 (13.1) 1241 (14.3)  
  Black or African American 15 (1.9) 13 (2.0) 28 (1.9) 161 (3.2) 147 (4.0) 308 (3.6)  
  Other* 28 (3.5) 20 (3.0) 48 (3.3) 306 (6.1) 224 (6.1) 530 (6.1)  
Current smoker, n (%) 118 (14.7) 112 (17.0) 230 (15.7) 902 (18.1) 674 (18.3) 1576 (18.2) 0.025
History of hypertension, n (%) 766 (95.4) 626 (95.1) 1392 (95.3) 4422 (88.6) 3311 (89.8) 7733 (89.1) <0.001
Duration of diabetes mellitus, y, mean (SD)§ 11.9 (7.9) 12.2 (7.7) 12.0 (7.8) 13.7 (7.7) 13.9 (7.8) 13.8 (7.7) <0.001‖
Microvascular disease history, n (%)
  Retinopathy 271 (33.7) 242 (36.8) 513 (35.1) 932 (18.7) 684 (18.5) 1616 (18.6) <0.001
  Nephropathy 210 (26.2) 185 (28.1) 395 (27.0) 784 (15.7) 595 (16.1) 1379 (15.9) <0.001
  Neuropathy 412 (51.3) 353 (53.6) 765 (52.4) 1375 (27.5) 970 (26.3) 2345 (27.0) <0.001
Atherosclerotic vascular disease history, n (%)†
  Coronary 681 (84.8) 529 (80.4) 1210 (82.8) 2553 (51.1) 1958 (53.1) 4511 (52.0) <0.001
  Cerebrovascular 280 (34.9) 216 (32.8) 496 (34.0) 833 (16.7) 629 (17.1) 1462 (16.8) <0.001
  Peripheral 266 (33.1) 223 (33.9) 489 (33.5) 910 (18.2) 714 (19.4) 1624 (18.7) <0.001
  Any 757 (94.3) 608 (92.4) 1365 (93.4) 3370 (67.5) 2589 (70.2) 5959 (68.6) <0.001
Cardiovascular disease history, n (%)‡ 658 (81.9) 516 (78.4) 1174 (80.4) 3098 (62.1) 2384 (64.6) 5482 (63.2) <0.001
History of atrial fibrillation, n (%) 110 (13.7) 101 (15.4) 211 (14.4) 241 (4.8) 161 (4.4) 402 (4.6) <0.001
History of amputation, n (%) 16 (2.0) 20 (3.0) 36 (2.5) 120 (2.4) 82 (2.2) 202 (2.3) 0.749
Body mass index, kg/m2, mean (SD)§ 33.1 (5.9) 33.2 (5.9) 33.2 (5.9) 31.8 (5.9) 31.7 (5.9) 31.8 (5.9) <0.001‖
Systolic blood pressure, mm Hg, mean (SD) 136.9 (14.9) 136.5 (14.3) 136.7 (14.6) 136.4 (15.9) 137.0 (16.0) 136.6 (15.9) 0.800
Diastolic blood pressure, mm Hg, mean (SD) 79.9 (9.5) 79.3 (9.4) 79.6 (9.4) 77.3 (9.6) 77.5 (9.7) 77.4 (9.7) <0.001
Glycated hemoglobin, %, mean (SD) 8.4 (1.0) 8.4 (1.0) 8.4 (1.0) 8.2 (0.9) 8.2 (0.9) 8.2 (0.9) <0.001‖
LDL cholesterol, mmol/L, mean (SD)§ 2.6 (1.1) 2.6 (1.1) 2.6 (1.1) 2.2 (0.9) 2.2 (0.9) 2.2 (0.9) <0.001‖
LDL/HDL cholesterol ratio, mean (SD)§ 2.3 (1.0) 2.3 (1.1) 2.3 (1.0) 2.0 (0.9) 2.0 (0.9) 2.0 (0.9) <0.001‖
Estimated glomerular filtration rate,  
mL/min/1.73 m2, mean (SD)§
72.7 (19.5) 73.3 (19.8) 73.0 (19.6) 77.3 (20.3) 76.7 (21.0) 77.1 (20.6) <0.001‖
Micro- or macroalbuminuria, n (%)§ 263 (33.3) 208 (32.2) 471 (32.8) 1465 (29.6) 1090 (29.9) 2555 (29.7) 0.019
Concomitant drug therapies, n (%)
  Diuretic 488 (60.8) 390 (59.3) 878 (60.1) 2048 (41.0) 1564 (42.4) 3612 (41.6) <0.001
  Loop diuretic 201 (25.0) 178 (27.1) 379 (25.9) 515 (10.3) 414 (11.2) 929 (10.7) <0.001
  Renin-angiotensin-aldosterone system 
blocker
680 (84.7) 572 (86.9) 1252 (85.7) 3965 (79.4) 2899 (78.6) 6864 (79.1) <0.001
  β-Blocker 566 (70.5) 463 (70.4) 1029 (70.4) 2473 (49.5) 1919 (52.0) 4392 (50.6) <0.001
  Statin 558 (69.5) 448 (68.1) 1006 (68.9) 3772 (75.6) 2822 (76.5) 6594 (76.0) <0.001
  Antithrombotic 680 (84.7) 553 (84.0) 1233 (84.4) 3556 (71.2) 2682 (72.7) 6238 (71.9) <0.001
  Insulin 383 (47.7) 320 (48.6) 703 (48.1) 2507 (50.2) 1885 (51.1) 4392 (50.6) 0.080
  Metformin 542 (67.5) 451 (68.5) 993 (68.0) 3905 (78.2) 2927 (79.3) 6832 (78.7) <0.001
  Sulfonylurea 376 (46.8) 287 (43.6) 663 (45.4) 2152 (43.1) 1546 (41.9) 3698 (42.6) 0.047
  Thiazolidinedione 14 (1.7) 6 (0.9) 20 (1.4) 293 (5.9) 179 (4.9) 472 (5.4) <0.001
(Continued )
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Effects of Canagliflozin on Heart Failure 
Outcomes (Overall and in Patient 
Subgroups)
Compared with placebo, canagliflozin was associ-
ated with significantly lower risks of cardiovascular 
death or hospitalized heart failure (HR, 0.78; 95% CI, 
0.67–0.91), fatal or hospitalized heart failure (HR, 0.70; 
95% CI, 0.55–0.89), as well as hospitalized heart fail-
ure alone (HR, 0.67; 95% CI, 0.52–0.87). There was 
no clear separate effect on fatal heart failure (HR, 0.89; 
95% CI, 0.49–1.60) for which there were few events 
and wide CIs (Figure 1). A subsidiary analysis of the pri-
mary outcome that accounted for competing mortality 
resulted in an HR estimate of 0.66 (95% CI, 0.51–0.84). 
The benefit on cardiovascular death or hospitalized 
heart failure was borderline significantly (P interaction 
=0.021) greater in patients with a prior history of heart 
failure (HR, 0.61; 95% CI, 0.46–0.80) compared with 
those without heart failure at baseline (HR, 0.87; 95% 
CI, 0.72–1.06; Figure 2). The absolute risk differences 
were –106.97 (95% CI, –171.59 to –42.34) per 1000 
patient-years for participants with a history of heart fail-
ure at baseline and –8.36 (95% CI, –22.08 to 5.36) per 
1000 patient-years for participants without a history of 
heart failure at baseline (P interaction =0.003).
Rates of heart failure varied according to baseline 
characteristics such as age, renal function, and other 
disease history characteristics, but effects of cana-
gliflozin on cardiovascular death or hospitalized heart 
failure were mostly comparable across participant 
subgroups (Figure  3). Nominally significant interac-
tion was observed with respect to the cardiovascular 
death or hospitalized heart failure outcome for several 
subgroups, including patients with higher versus lower 
body mass index, lower versus higher baseline glyco-
hemoglobin, with versus without background use of 
diuretic therapy, and with versus without background 
metformin use (all P interaction >0.02; Figure 3). Par-
ticipants randomized to canagliflozin treatment had 
less recurrent hospitalizations for heart failure during 
follow-up compared with participants assigned to pla-
cebo (HR, 0.68; 95% CI, 0.47–0.96). In the CANVAS 
trial, in which participants were assigned at random to 
placebo, canagliflozin 100 mg, or canagliflozin 300 mg, 
there was no evidence that the effects on cardiovascu-
lar death or hospitalized heart failure varied by dose 
(100 mg versus placebo: HR, 0.82; 95% CI, 0.65–1.03; 
and 300 mg versus placebo: HR, 0.82; 95% CI, 0.65–
1.03). Among the subset of participants who reported 
a history of heart failure and loop diuretic use at base-
line (n=379), the HR for the primary outcome was 0.54 
(95% CI, 0.37–0.78).
Effects of Canagliflozin on 
Cardiovascular, Kidney, and Death 
Outcomes in Patients With and Without 
Heart Failure at Baseline
Proportional effects of canagliflozin compared with 
placebo were comparable in patients with and without 
heart failure at baseline for major adverse cardiovascu-
lar events, cardiovascular death, myocardial infarction, 
stroke, all-cause mortality, and serious decline in kidney 
function (all P interaction >0.160; Figure  2). Patients 
with a history of heart failure were at higher absolute 
risk of most outcomes. Although the numeric values 
for risk differences were typically greater among par-
ticipants with a history of heart failure compared with 
those without, none reached statistical significance (all 
P interaction >0.130).
Safety Outcomes
Compared with placebo, canagliflozin has established 
associations with increased risks of amputation, frac-
ture, and volume depletion, but there was no evidence 
of proportional differences in these risks between pa-
tients with and without heart failure at baseline (all P 
  Dipeptidyl peptidase-4 inhibitor 56 (7.0) 54 (8.2) 110 (7.5) 641 (12.8) 510 (13.8) 1151 (13.3) <0.001
  Glucagon-like peptide-1 receptor agonist 14 (1.7) 12 (1.8) 26 (1.8) 208 (4.2) 173 (4.7) 381 (4.4) <0.001
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and SD, standard deviation. 
*Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple races, other races, and unknown race. 
†Some participants had ≥1 type of atherosclerotic disease.
‡As defined in the protocol. 
§Values for duration of diabetes mellitus categories were calculated based on 5790 patients for canagliflozin, 4341 for placebo, and 10 131 for the total 
population. Values for body mass index categories were calculated based on 5787 patients for canagliflozin, 4341 for placebo, and 10 128 for the total population. 
Values for LDL cholesterol categories were calculated based on 5731 patients for canagliflozin, 4287 for placebo, and 10 018 for the total population. Values for 
estimated glomerular filtration rate categories were calculated based on 5794 patients for canagliflozin, 4346 for placebo, and 10 140 for the total population. 
Values for albuminuria categories were calculated based on 5740 patients for canagliflozin, 4293 for placebo, and 10 033 for the total population. 
‖Comparison of heart failure versus non–heart failure was analyzed with a Wilcoxon 2-sample test.
Table. Continued
Variable
Participants With Heart Failure Participants Without Heart Failure P Value 
Heart Failure 
vs No Heart 
Failure
Canagliflozin
(n=803)
Placebo
(n=658)
Total
(n=1461)
Canagliflozin
(n=4992)
Placebo
(n=3689)
Total
(n=8681)
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interaction >0.160; Figure 4). The absolute risk of os-
motic diuresis-related events, another established risk 
of therapy, was significantly lower in patients with a 
history of heart failure compared with those without (P 
interaction =0.029; Figure 4).
DISCUSSION
Patients with type 2 diabetes mellitus and established 
cardiovascular disease or at high risk of cardiovascu-
lar events who were treated with canagliflozin expe-
rienced significantly reduced rates of cardiovascular 
death or hospitalized heart failure. Benefits may be 
greater in those with a history of heart failure com-
pared with those without. Effects were apparent 
across a broad range of participant subgroups, in-
cluding those using established treatments for the 
prevention of heart failure, such as blockade of the 
renin angiotensin aldosterone system, diuretics, and 
β-blockers.
Other cardiovascular outcomes and death generally 
occurred more frequently in patients with a history of 
heart failure compared with those without, but both 
sets of participants experienced comparable reduc-
tions in the risks of these outcomes with the use of 
canagliflozin. Labeled adverse effects of canagliflozin 
on amputation and fracture were comparable among 
patients with and without heart failure at baseline, 
but there were possibly lower absolute risks of adverse 
events related to osmotic diuresis among patients with 
heart failure. There was no statistical evidence that ad-
verse events attributable to volume depletion or acute 
kidney injury were differentially increased by treatment 
with canagliflozin in those with heart failure compared 
with those without heart failure, although CIs about 
estimates were wide.
The benefits for heart failure outcomes appeared 
early during follow-up, suggesting a mode of action 
driven primarily by volume and hemodynamic effects. 
Reductions in preload and afterload stemming from 
natriuresis,14 systemic blood pressure lowering,17 modi-
fication of the intrarenal renin angiotensin axis,18 and 
reduction in arterial stiffness19 may all contribute to the 
protection afforded. Preservation of renal function and 
Figure 1. Effects of canagliflozin on heart failure outcomes. 
A through D, Effects of canagliflozin on cardiovascular death or hospitalized heart failure (A), fatal or hospitalized heart failure 
(B), fatal heart failure (C), and hospitalized heart failure (D). CI indicates confidence interval.
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the mitigation of volume overload achieved with SGLT2 
inhibition also probably contributed to the observed 
reduction in heart failure risk. By contrast, antiathero-
sclerotic effects of SGLT2 inhibition mediated through 
effects on glucose, blood pressure, and obesity are un-
likely to have played a major role in the large and early 
benefit observed for this outcome.
There may also be direct positive effects of SGLT2 in-
hibition on cardiac metabolism that are attributable to a 
shift from fatty acids to ketone bodies as the substrate 
for myocardial energy generation. Metabolic studies 
have shown that the hypertrophied and failing heart 
uses ketone bodies as an alternate fuel source,20,21 and 
increased hepatic neogenesis of ketone bodies is an es-
tablished effect of SGLT2 inhibitors.22,23 Enhanced car-
diac efficiency may also be facilitated by increased oxy-
gen delivery resulting from SGLT2 inhibitor–associated 
hemoconcentration.18 Although the SGLT2 receptor is 
expressed primarily on the luminal surface of the proxi-
mal tubule in the kidney, there has been 1 report of 
SGLT2 expression in heart tissue.24
The findings reported here are strengthened by 
the rigorous design and conduct of the trial, the pre-
specification of heart failure as an outcome of inter-
est, and the careful masked adjudication of all rele-
vant events by an expert committee. Capturing the 
different modes of heart failure death as a separate 
cause-specific outcome is challenging and may un-
derestimate the fatal disease burden attributable to 
heart failure. Accordingly, we selected the composite 
of cardiovascular death and hospitalized heart failure 
as the primary outcome because of its clinical rel-
evance while also reporting on other more narrowly 
defined outcomes incorporating events explicitly de-
fined as heart failure death. The relatively few primary 
outcome events recorded limits the capacity to detect 
effects and makes difficult interpretation of border-
line significant findings (eg, the interactions of cana-
gliflozin treatment and heart failure prevention with 
baseline characteristics, such as obesity and use of 
some drug therapies). Interpretation is further compli-
cated by the overlap in these baseline characteristics 
Figure 2. Proportional and absolute effects of canagliflozin compared with placebo on cardiovascular and renal 
outcomes in patients with and without a history of heart failure at baseline. 
ARD indicates absolute risk difference over 5 years; CI, confidence interval; HF, heart failure; and HR, hazard ratio. *HR (cana-
gliflozin compared to placebo) and its 95% CI are estimated using a Cox proportional hazard model including treatment as 
the explanatory variable. The model for CV death is stratified by prior CV disease subgroup and study. The models of renal 
endpoints are stratified for stage of baseline chronic kidney disease, measured by estimated glomerular filtration rate (<60, 
≥60 mL/min/1.73 m2) and by study. †Serious decline in kidney function was defined as a 40% reduction in the estimated glo-
merular filtration rate, the need for renal replacement therapy, or death from renal causes.
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across participant subgroups. The limited documenta-
tion of heart failure at baseline, and  specifically the ab-
sence of systematically collected baseline biomarkers 
or echocardiography data, meant that the estimated 
prevalence of established heart failure was imperfect 
and there was likely some misclassification of patients 
according to the presence or absence of heart failure 
at baseline. It was also not possible to classify baseline 
heart failure according to preservation or reduction in 
ejection fraction. The low rates of loop diuretic use 
among patients with heart failure at baseline suggests 
that most had nonsevere disease and raises additional 
uncertainty about the heart failure diagnoses at base-
line in some patients.
The effects on heart failure observed within the 
CANVAS Program appear mostly comparable to those 
Favors Favors
Placebo
HR (95% CI)
P
interaction
Study
 CANVAS
 CANVAS-R
Age
 <65 years
 ≥65 years
Region
 North America
 Central America and South America
 Europe
 Rest of world
BMI
 <30 kg/m2
 ≥30 kg/m2
Blood pressure
 Systolic ≥140 mmHg or diastolic ≥90 mmHg
 Systolic <140 mmHg and diastolic <90 mmHg
Diabetes duration
 ≥10 years    
 <10 years
Baseline glycated hemoglobin
 <8%
 ≥8%
Baseline eGFR
 30-60 mL/min/1.73 m2
 60-90 mL/min/1.73 m2
 ≥90 mL/min/1.73 m2
History of CV disease
 Yes
 No
 Yes
 No
Baseline insulin use
 Yes
 No
Baseline metformin use
 Yes
 No
Baseline DPP-4 inhibitor use
 Yes
 No
Baseline thiazolidinedione use
 Yes
 No
Baseline RAAS use
 Yes
 No
Baseline β-blocker use
 Yes
 No
Baseline diuretic use
 Yes
 No
Baseline loop diuretic use
 Yes
 No
Baseline non-loop diuretic use
 Yes
 No
0.82 (0.67, 0.99)
0.72 (0.55, 0.94)
0.65 (0.51, 0.83)
0.87 (0.71, 1.07)
0.87 (0.63, 1.20)
0.84 (0.50, 1.43)
0.74 (0.57, 0.95)
0.75 (0.56, 1.01)
1.01 (0.76, 1.34)
0.68 (0.56, 0.82)
0.72 (0.58, 0.91)
0.84 (0.68, 1.05)
0.79 (0.66, 0.94)
0.75 (0.54, 1.03)
0.97 (0.75, 1.24)
0.68 (0.55, 0.83)
0.75 (0.57, 0.98)
0.86 (0.69, 1.08)
0.65 (0.43, 0.96)
0.77 (0.65, 0.92)
0.83 (0.58, 1.19)
0.72 (0.49, 1.05)
0.79 (0.66, 0.94)
0.77 (0.63, 0.94)
0.80 (0.63, 1.03)
0.88 (0.72, 1.08)
0.64 (0.50, 0.82)
0.58 (0.33, 1.04)
0.80 (0.68, 0.94)
0.99 (0.43, 2.33)
0.77 (0.66, 0.91)
0.78 (0.66, 0.93)
0.78 (0.53, 1.16)
0.70 (0.58, 0.85)
0.96 (0.73, 1.26)
0.71 (0.58, 0.86)
0.93 (0.72, 1.21)
0.72 (0.55, 0.93)
0.83 (0.68, 1.01)
0.71 (0.53, 0.96)
0.81 (0.67, 0.97)
0.46
0.09
0.69
0.03
0.30
0.74
0.04
0.41
0.42
0.47
0.96
0.03
0.20
0.55
0.93
0.06
0.03
0.18
0.53
Patients per
1000 patient-years
Placebo
Number of
events
427
225
259
393
161
56
247
188
211
439
312
340
495
155
254
652
226
325
101
524
128
113
539
392
260
394
258
49
603
25
627
548
104
428
224
408
244
231
421
177
475
16.4
15.9
10.4
24.4
16.8
20.5
17.5
13.8
14.2
17.5
17.1
15.7
17.7
12.6
15.2
17.1
31.6
14.7
9.7
21.0
8.9
50.9
14.3
19.7
12.9
13.5
24.8
9.8
17.0
10.9
16.7
17.1
13.0
19.7
12.6
22.0
11.9
47.9
12.4
13.2
17.7
19.9
21.9
15.5
27.9
18.2
25.4
23.9
18.3
14.5
25.1
23.8
18.3
22.6
16.6
16.1
24.6
41.4
16.8
14.3
27.4
9.8
72.6
17.9
25.0
16.5
15.4
39.1
17.9
21.1
9.8
21.5
21.8
16.8
27.8
13.1
31.7
12.1
69.1
14.3
18.1
22.1
0.25 0.50 1.0 2.0 4.0
Figure 3. Effects on cardiovascular death or hospitalized heart failure in subgroups defined by demographic and 
disease characteristics. 
History of CV disease‒yes indicates patients were included on the basis of atherosclerotic cardiovascular disease history, 
whereas history of CV disease–no indicates patients were included on the basis of risk factors alone. BMI indicates body mass 
index; CANVAS, Canagliflozin Cardiovascular Assessment Study; CANVAS-R, Canagliflozin Cardiovascular Assessment Study–
Renal; CI, confidence interval; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; 
HR, hazard ratio; and RAAS, renin angiotensin aldosterone system. 
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reported for the EMPA-REG OUTCOME trial. An ex-
ception was the observation of a borderline signifi-
cant greater proportional risk reduction for individu-
als with a history of heart failure at baseline in the 
CANVAS Program, which was not matched by a 
corresponding finding in the analyses of the EMPA-
REG OUTCOME trial. This might reflect the different 
characteristics of the included populations or the 
slightly different criteria used to define heart failure 
outcomes between the 2 studies. However, the mul-
tiple and post hoc analyses of heart failure done for 
the CANVAS Program and EMPA-REG OUTCOME had 
limited statistical power to test for interactions, and 
the risk of missing real differences or observing spuri-
ous chance differences is high.
The CANVAS Program data provide clear evidence 
of the protective effects of canagliflozin on heart fail-
ure and, in conjunction with EMPA-REG OUTCOME, 
suggest an important role for SGLT2 inhibitors in the 
prevention of heart failure among patients with type 2 
diabetes mellitus. Additional data from ongoing trials in 
diabetes mellitus will further clarify the impact of SGLT2 
inhibitors on this major cause of mortality and morbid-
ity25,26 and confirm or refute hypotheses raised by the 
CANVAS and EMPA-REG OUTCOME trial findings. A 
series of new trials specifically exploring mechanisms 
and testing effects on heart failure outcomes among 
patients without diabetes mellitus27–30 will also provide 
further insight into the mode of action by which ben-
efits are achieved. In conclusion, among patients with 
type 2 diabetes mellitus and an elevated risk of cardio-
vascular disease, canagliflozin reduced the risk of car-
diovascular death or hospitalized heart failure across a 
broad range of different patient groups and in addition 
to concomitant therapies for heart failure. Benefits may 
be greater in patients with a baseline history of heart 
failure compared with those without a history of heart 
failure.
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Figure 4. Proportional and absolute effects of canagliflozin compared with placebo on key safety outcome in 
 patients with and without a history of heart failure at baseline. 
ARD indicates absolute risk difference over 5 years; CANVAS, Canagliflozin Cardiovascular Assessment Study; ITT, intent-to-
treat; CANVAS-R, Canagliflozin Cardiovascular Assessment Study–Renal; CI, confidence interval; HF, heart failure; and HR, 
hazard ratio. *Based on ITT dataset, whereas all other analyses based on on-treatment dataset. †For these adverse events, the 
annualized incidence rates are reported based on the CANVAS study alone through January 7, 2014, because, after this time, 
only serious adverse events or adverse events leading to discontinuation were collected. In the CANVAS-R study, only serious 
adverse events or adverse events leading to discontinuation were collected for these events.
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SUPPLEMENTAL MATERIAL 
Supplemental Appendix 1. CANVAS Program sites and investigators 
 
CANVAS 
 
Argentina: Pablo Arias, Maria Rosa Ulla, Andres Alvarisqueta, Laura Maffei, Jose Osvaldo 
Fretes, Silvia Gorban De Lapertosa, Virginia Visco, Georgina Sposetti, Javier Farias, Eduardo 
Francisco Farias, Maria Cecilia Cantero, Rodolfo Feldman, Maria Carolina Ridruejo, Pedro 
Calella, Cesar Zaidman; Australia: Stephen Stranks, Peak Man Mah, Alison Nankervis, Duncan 
Topliss, Georgia Soldatos, Richard Simpson, Murray Gerstman, David Colquhoun, Ferdinandus 
De Looze, Robert Moses, Michael Suranyi, Samantha Hocking, David Packham, Duncan Cooke, 
Karam Kostner; Belgium: Eric Weber, Chris Vercammen, Luc Van Gaal, Jozef Tits, Bart 
Keymeulen, Chantal Mathieu; Canada: Naresh Aggarwal, Dan Dattani, Francois Blouin, 
Richard Dumas, Sam Henein, Patrick Ma, Ali Najarali, Michael Omahony, Tracy Pella, Wilson 
Rodger, Daniel Shu, Vincent Woo, Brian Zidel, Lew Pliamm, Brian Ramjattan, Ronald Akhras, 
Jasmin Belle-Isle, Stuart Ross, Geza Molnar; Colombia: Juan Manual Arteaga, Ivonne Jarava; 
Czech Republic: Alena Andresova, Miloslava Komrskova, Cyril Mucha, Tomas Brychta, 
Dagmar Bartaskova, Romana Urbanova, Tomas Spousta, Jana Havelkova, Tomas Sedlacek, 
Milan Kvapil; Estonia: Ülle Jakovlev, Verner Fogel, Liina Viitas, Mai Soots, Maire Lubi, Marju 
Past, Jelena Krasnopejeva; Germany: Hasan Alawi, Klaus Busch, Felix Klemens Pröpper, 
Andrea Thron, Stephan Jacob, Andreas Pfützner, Ludger Rose, Thomas Segiet, Christine Kosch, 
Andrea Moelle; Great Britain: Melanie Davies, Hamish Courtney, Martin Gibson, Luigi Gnudi, 
Frances Game, John Wilding, Thozhukat Sathyapalan, Miles Fisher, Shenaz Ramtoola, Satyan 
Rajbhandari, Maurice Okane; Hungary: Eleonora Beke, Ferenc Poor, Karoly Nagy, Gyozo 
Kocsis, Tamas Oroszlan, Peter Faludi, Mihaly Gurzo; India: Sathyanarayana Srikanta, Mala 
Dharmalingam, Bala Murugan, Pramod Gandhi, Bipin Sethi, Sosale Aravind, Sharda 
Ardhanareeshwaran, Arpan Bhattacharyya, Ganapathi Bantwal, Vijay Viswanathan, Paramesh 
Shamanna, Banshi Saboo, Viswanathan Mohan, Reshma Parmaj, Kirti Kumar Modi, Sindhu 
Joshi, Sunil Jain, Sanjay Kalra, Arun Chankramath Somasekharan, Prabha Adhikari, Ajay 
Kumar, Harshada Kudalkar, Rajiv Passey, Mathew John, Sadasivarao Yalamanchi, Keyur 
Parikh, K.P. Rajesh, Rajesh Nair, Ajay Kumar, Sasi Kumar, Lily Rodrigues, Pawan Gangwal, 
Pankaj Agarwal, Sandeep Kumar Gupta, Abhay Amrutlal Mutha, Shailaja Dilip Kale, Ravindra 
Laxman Kulkarni, Sandip Chudasama, Kamal Sharma, Anoop Nambiar, Aniruddha Tangaonkar, 
Vaishali Deshmukh, Biswakesh Majumdar, Rajendran Veerappan, Deepak Namjoshi; Israel: 
Itamar Raz, Julio Weinstein, Ilana Harman Boehm, Victor Vishlitzky; Luxembourg: Frederic 
Dadoun; Malaysia: Rajesh P. Shah, Lai Seong Hooi, Alexander Tan, Wan Mohamad Wan 
Bebakar, Mafauzy Mohamed, Amir S. Khir, Norlela Sukor, Khalid Abdul Kadir; Mexico: 
Enrique Morales, Sergio Zuñiga, Melchor Alpizar, Cesar Calvo, Rolando Zamarripa, Juan Rosas, 
Armando Vargas; The Netherlands: Max Nieuwdorp, Vicdan Kose, Susanne Kentgens, Gloria 
Rojas, Wouter Van Kempen, Jacqueline Hoogendijk, Mazin Alhakim, Victor Gerdes, Marcel 
Hovens, Johan Berends, A. Woittiez, Cees Jan Smit, B. Dekkers, Wilco Spiering, Marcel K. Van 
Dijk-Okla, Ben P.M. Imholz, Ruud J.M. Van Leendert, Marije Ten Wolde, Peter J.H. Smak 
Gregoor; New Zealand: Russell Scott, Jeremy Krebs, John Baker, Joe Singh, Calum Young; 
Norway: Gisle Langslet, Hans Olav Hoivik, Torbjorn Kjaernli, Sigbjorn Elle, Eric Gjertsen, 
Knut Risberg, Andreas Tandberg, Leidulv Solnoer, Per Anton Sirnes; Poland: Tadeusz 
Derezinski, Malgorzata Arciszewska, Edward Franek, Ewa Szyprowska, Dariusz Sowinski, 
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Robert Petryka, Beata Czakanska-Dec, Grazyna Pulka, Katarzyna Jusiak, Mariusz Dabrowski, 
Piotr Kubalski, Malgorzata Wojciechowska, Andrzej Madej, Danuta Pupek-Musialik; Russia: 
Natalia Blinova, Ludmila Kondratjeva, Anatoly Kuzin, Mikhail Boyarkin, Tatyana Gomova, 
Alexander Khokhlov, Sergey Vorobjev, Olga Mirolyubova, Svetlana Boldueva, Olga Ershova, 
Marina Ballyzek, Olga Smolenskaya, Sergey S. Yakushin, Dmitry Zateyshchikov, Mikhail 
Arkhipov, Alexandr Kuzmenko, Ivan Maksimov, Igor Motylev, Vladimir Rafalskiy, Leonid 
Strongin, Tatyana Treshkur, Natalya Volkova, Olga Barbarash, Tatiana Raskina, Leonid Bartosh, 
Inna Nikolskaya, Elena Shutemova, Viktor Gurevich, Natalia Burova, Elena Vorobyeva, Denis 
Andreev, Boris Bart, Tatiana Khlevchuk, Lyudmila Gapon, Ivan Gordeev, Nikolai Gratsiansky, 
Alsu Zalevskaya, Sergey Sayganov, Oleg Solovyev, Galina Reshedko, Natalia Shilkina, Petr 
Chizhov, Julia Shapovalova, Alexander Sherenkov, Olga Reshetko, Vladimir Simanenkov; 
Spain: Juan Garcia Puig, Jose Saban, Jose Pascual, Jose Dominguez, Elias Delgado, Carlos 
Calvo, Manuel Vida, Santiago Duran, Francisco Tinahones, Jordi Salas, Jose Miguel Gonzalez, 
Manuel Monreal, Armand Grau, Andreu Nubiola, Pere Alvarez; Sweden: Kaj Stenlöf, Pekka 
Koskinen, Carl-Johan Lindholm, Ulrik Mathiesen, Katarina Berndtsson Blom, Bengt-Olov 
Tengmark, Hans Jul-Nielsen; Ukraine: Oleksandr Larin, Svetlana Panina, Svitlana Kovalenko, 
Olena Voloshyna, Vera Tseluyko, Olga Gyrina, Vadim Vizir, Olga Barna, Maryna Dolzhenko, 
Yuriy Mostovoy, Vadim Korpachev, Boris Mankovskiy, Mykola Vatutin; United States: 
Charles Arena, Basil Akpunonu, Rahfa Zerikly, Claire Baker, Toby Briskin, Darlene Bartilucci, 
Joshua Barzilay, Christian Breton, John Buse, Richard Cherlin, Michael Cobble, Clarence Ellis, 
Raymond Fink, Alan Forker, Ronald Garcia, Priscilla Hollander, Angela House, Daniel Hyman, 
Richard Ingebretsen, David Jack, Judith Kirstein, Kerri Kissell, Daniel Lorber, Donald McNeil, 
Wendell Miers, Alex Murray, Robert Call, Stephen T. Ong, Fernando Ovalle, Robert Pearlstein, 
Veronica Piziak, Daniel Pomposini, David Robertson, Julio Rosenstock, Ulrich Schubart, 
Shaukat Shah, Rodney Stout, Mark Turner, James Wallace, Leonard Chuck, Edmund Claxton, 
Emily Morawski, Alan Wynne, Carol Wysham, Michael Alderman, Walter Patton, Bryan Pogue, 
Arnold Silva, Roger Guthrie, Sam Lerman, Robert Madder, Wendy Miller, Daniel Weiss, Dean 
Kereiakes, Ronald J Graf, Negah Rassouli, James Greenwald, Hanna Abu-Nassar, Derek Muse, 
Vicki Kalen, Natalia Hegedosh, Richard Dobrusin, Glover Johnson, Tami Bruce, Gary Gleason.  
 
CANVAS-R  
 
Argentina: Marisa Vico, Sonia Hermida, Lucrecia Nardone, Laura Maffei, Javier Farias, 
Elizabeth Gelersztein, Maximiliano Sicer, Andres Alvarisqueta, Georgina Sposetti, Virginia 
Visco, Rodolfo Feldman, Silvia Orio; Australia: Christopher Nolan, Michael Suranyi, Samantha 
Hocking, Stephen Stranks, Duncan Cooke, Ferdinandus de Looze, Ashim Sinha, Timothy Davis, 
Anthony Russell, Acharya Shamasunder, Murray Gerstman, Richard MacIsaac; Belgium: Chris 
Vercammen, Luc Van Gaal, Chantal Mathieu, Xavier Warling, Jan Behets, Andre Scheen, Guy 
T’Sjoen, Ann Verhaegen, Isabelle Dumont, Youri Taes, Francis Duyck, Fabienne Lienart; 
Brazil: Adolfo Sparenberg, Adriana Costa e Forti, Andressa Leitao, Cariolina Jungers di 
Siqueira Chrisman, César Hayashida, Daniel Panarotto, Fabio Rossi dos Sanos, Fadlo Fraige 
Filho, Flávia Coimbra Maia, Gilmar Reis, Hugo Lisboa, Joao Felicio, Joselita Siqueira, Lilia 
Nigro Maia, Luiz Alberto Andreotti Turatti, Maria José Cerqueira, Maria Tereza Zanella, 
Patricia Muszkat, Miguel Nasser Hissa, Teresa Bonansea; Canada: Igor Wilderman, Vincent 
Woo, Richard Dumas, Francois Blouin, Pierre Filteau, George Tsoukas, Peter Milne, Dan 
Dattani, Chantal Godin, Michael Omahony, Daniel Shu, Jasmin Belle-Isle, Douglas Friars, Anil 
 3 
 
Gupta, Ted Nemtean, Andrew Steele; China: Zhan-Quan Li, Changsheng Ma, Linong Ji, 
Shuguang Pang, Yan Jing, Ruiping Zhao, Ruifang Bu; Czech Republic: Tomas Spousta, Tatana 
Souckova, Dagmar Bartaskova, Pavlina Kyselova, Lea Raclavska, Milan Kvapil, Jana 
Havelkova, Emilia Malicherova; France: Philippe Zaoui, Didier Gouet, Jean-Pierre Courreges, 
Salha Fendri, Samy Hadjadj, Bruno Verges, Bogdan Nicolescu Catargi, Sylvaine Clavel, Jean-
Jacques Altman, Agnes Hartemann, Gaétan Prevost; Germany: Diethelm Tschöpe, Elena 
Henkel, Rolf Göbel, Jochen Seufert, Hermann Haller, Thomas Behnke, Andreas Pfützner, 
Gerhard Klausmann, Klaus Busch, Baerbel Hirschhaeuser, Stephan Jacob; Great Britain: 
Melanie Davies, Rob Andrews, Narayan Annamalai, Hamish Courtney, Srikanth Bellary, Mark 
Blagden, John Clark, Steven Creely, Ken Darzy, Iskandar Idris, Richard Falk, Lucinda Summers, 
Njaimeh Asamoah, Andrew Johnson, See Kwok, Shenaz Ramtoola, Gerry Rayman, Jamie 
Smith, John Wilding; Hungary: Marietta Baranyai, Katalin Csomos, Mihaly Gurzo, Eleonóra 
Harcsa, Nikosz Kanakaridisz, Nóra Késmárki, Tamas Oroszlan, József Pátkay, Eva Peterfai, 
Balázs Gaszner, Ildiko Jozsef; Italy: Stefano Genovese, Antonio Ettore Pontiroli, Enzo Bonora, 
Dario Giugliano, Domenico Cucinotta, Giorgio Sesti, Paola Ponzani, Giuseppe Pugliese, Giulio 
Marchesini Reggiani, Paolo Pozzilli, Sergio Leotta, Emanuela Orsi, Carlo Giorda, Paolo Di 
Bartolo; Korea: Tae-Sun Park, Chung-Gu Cho, In-Joo Kim, Il Seong Nam-Goong, Choon Hee 
Chung, Ho Chan Cho, Dong-Seop Choi, Kun-Ho Yoon, Nan-Hee Kim, Kyung-Mook Choi, Kyu-
Jeung Ahn, Ji-Oh Mok, Soon-Jib Yoo, Tae-Keun Oh, Kwan-Woo Lee, Hak-Chul Jang, Jeong-
Hyun Park, In-Kyu Lee, Byung-Joon Kim, Doo-Man Kim, Ho Sang Shon, Moon-Kyu Lee, 
ShinGon Kim; Malaysia: Mafauzy Mohamed, Paranthaman Vengadasalam, Alexander Tong 
Boon Tan, Wan Mohd Izani Wan Mohamed, Rajesh P Shah, Khalid Yusoff, Amir Sharifuddin 
Mohd Khir, Florence Tan, Mansor Yahya; Mexico: Rafael Violante, Manuel Odin De los Rios, 
Marco Alcocer, Enrique Morales, Juan Rosas, Armando Vargas, Manuel González, Esperanza 
Martinez, Jorge Antonio Aldrete, Guillermo Gonzalez, Cynthia Mustieles Rocha, Leobardo 
Sauque, Paul Frenk, José Luis Arenas; The Netherlands: Peter Tichelaar, A Kooy, Albert Van 
de Wiel, Gerben Lochorn, Peter De Vries, Hans Feenstra, Max Nieuwdorp, Wouter Van 
Kempen, Mazin Alhakim, Ben Imholz, Ruud van Leendert, Peter Smak Gregoor, Joop Brussen, 
Hanno Pijl, Manuel Castro Cabezas, F Gonkel, P Smits, Daan Lansdorp, Susanne Kentgens, 
Aletha Veenendaal, Gloria Rojas; New Zealand: John Richmond, Russell Scott, Mike Williams, 
Dean Quinn, Jeremy Krebs, John Baker, Veronica Crawford, Calum Young; Poland: Malgorzata 
Arciszewska, Krystyna Jedynasty, Dariusz Sowinski, Ewa Szyprowska, Andrzej Madej, 
Miroslawa Polaszewska-Muszynska, Danuta Zytkiewicz-Jaruga, Katarzyna Wasilewska, Piotr 
Romanczuk, Anna Ocicka-Kozakiewicz, Czeslaw Marcisz, Boguslaw Okopien, Anna Bochenek, 
Lukasz Wojnowski, Teresa Sliwinska, Barbara Rewerska, Witold Zmuda, Katarzyna Klodawska, 
Ewa Skokowska, Jacek Fabisiak, Cezary Danilkiewicz; Puerto Rico: Elba Perez Vargas, 
Elizabeth Barranco Santana; Russia: Tatiana Raskina, Olga Barbarash, Leonid Bartosh, Igor 
Motylev, A Kuzin, Olga Reshetko, Tatyana Zykova, Olga Ershova, Marina Balyzek, Vladimir 
Rafalsky, Natalya Volkova, Nina Nosova, Natalia Burova, Alsu Zalevskaya, Galina Reshedko, 
Natalia Shilkina, Petr Chizhov, Alexander Sherenkov,  Vladimir Simanenkov, Tatiana Lysenko, 
Irina Ipatko, Mikhail Boyarkin, Sergey Vorobyev, Lyudmila Gapon, Andrey Obrezan, Valeria 
Esip, Zhanna Paltsman, Andrey Verbovoy, Fatima Khetagurova, Yuri Shvarts; Spain: Pere 
Alvarez-Garcia, Francisco Martinez Deben, Josep M Grinyo, Carlos Calvo, Carmen Suarez, JM 
Pascual, Jose Dominguez, Anna Oliveras, Armand Grau, Fernando Gómez Peralta, Luis Alvarez-
Sala, Cañizo Francisco, Jorge Gómez Cerezo, Juan Garcia Puig, Carlos Trescolí, Francisco Jose 
Fuentes Jimenez, Santiago Tofé, Judith López, Javier Nieto Iglesias, Luis Vigil, Santiago Duran 
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Garcia, Jose Luis Gorriz, Pilar Saavedra Vallejo, Francisco Tinahones Madueno, Jose Luis 
Blanco Coronado, Alfonso Soto, Luis De Teresa, Jose Miguel Gonzalez, Antonio Rodriguez 
Botaro, Carmina Cuesta; Sweden: Bjorn Bragée, Bengt-Olov Tengmark, Hans Jul-Nielsen, 
Pekka Koskinen, Linda Moris, Fredrik Huss, Pär Jennersjö, Katarina Berndtsson-Blom, Bo Liu, 
Kaj Stenlöf, Carl-Johan Lindholm, Johan Jendle; Taiwan: Dee Pei, Wayne H-H Shue, Chern-En 
Chiang, Ching-Chu Chen, Ming-Nan Chien, Ping-Yen Liu, Ching-Ling Lin, Yi-Jing Sheen; 
Ukraine: Dmytro Reshotko, Nikolay Rishko, Olexander Samoylov, Valentina Serkova, Ivan 
Smirnov, Liubov Sokolova, Vira Tseluyko, Vadym Vizir, Tetiana Zlova, Vitaliy Maslyanko, 
Oleksandr Larin, Valentina Velichko, Lyudmila Prystupa, Nadiya Yarema, Galina Mishanich, 
Iryna Bondarets, Nataliya Virstyuk, Olexander Serhiyenko, Stepan Pavlyk, Olena Levchenko, 
Orest Abrahamovych, Volodymyr Botsurko, Maryna Dolzhenko, Victoria Chernikova, Yuriy 
Karachentsev, Vitaliy Katerenchuk, Vadym Korpachov, Yaroslav Malynovsky, Boris 
Mankovsky, Yuriy Mostovoy, Larisa Pererva, Nataliya Pertseva; United States: Vicki Conrad, 
Kenneth Fox, David Jack, Robert Buynak, Michael Dever, John Kirby, Larry Odekirk, Priyantha 
Wijewardane, Robert Carson, Bruce Seaton, Ann Elizabeth Mohart, Salvatore Bianco, Michael R 
Cox, Andrew Kim, Steven Geller, Jakkidi Reddy, Derek Muse, Alan Wynne, Harold Bays, 
Judith Kirstein, James Riser, Ahmed Arif, Claire Baker, Kim Barbel-Johnson, Gary Bedel, Pierre 
Blemur, Christian Breton, Anna Chang, Brian Naccari, Nancy Jo Coburn, Lisa Cohen, Eric 
Dedeke, Charles Diederich, John Earl, Anu George, Matthew Gilbert, Gary Gleason, Gregory 
Haase, Rodney Ison, Mahendra Jain, Imtiaz Alam, Sam Lerman, Lawrence Levinson, Lon D 
Lynn, Michael Oliver, Barry Kusnick, Robert Pearlstein, Sanford Plevin, Samuel Mujica 
Trenche, Vernon Young, Michael Jutovsky, Ralph Wade, James Wallace, Albert Weisbrot, 
Duane Wombolt, Alan Forker, Jalal Taslimi, Roger Guthrie. 
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Supplemental Appendix 2. CANVAS Program committees 
 
Steering Committee 
David R. Matthews (Co-chair), Bruce Neal (Co-chair), Greg Fulcher, Kenneth W. Mahaffey, 
Vlado Perkovic, Mehul Desai (Sponsor), Dick de Zeeuw 
 
Independent Data Monitoring Committee 
Philip Home (Chair), Jeffrey L. Anderson, Ian W. Campbell, John Lachin (withdrew in 
September 2015), Daniel Scharfstein, Scott D. Solomon, Robert G. Uzzo 
 
Cardiovascular Adjudication Committee 
Greg Fulcher (Chair), John Amerena,  Clara Chow,  Gemma Figtree, John French, Graham 
Hillis, Mark A. Hlatky, Bronwyn Jenkins, Nicholas J. Leeper, Richard Lindley, Barry McGrath, 
Alison Street, John Watson 
 
Renal Adjudication Committee 
Greg Fulcher (Chair), Shahnaz Shahinfar, Tara Chang, Arjun D. Sinha, Phyllis August 
 
Safety Adjudication  
Fracture Adjudication: Bioclinica 
Diabetic Ketoacidosis Adjudication: Baim Institute for Clinical Research  
Pancreatitis Adjudication Committee: Adam Cheifetz (Chair), Sunil Sheth, Joseph Feuerstein 
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Supplemental Appendix 3. CANVAS Program cardiovascular death and heart failure 
criteria 
 
Definition of Cardiovascular Death 
Cardiovascular death includes death resulting from an acute MI, sudden cardiac death, death 
due to heart failure, death due to stroke, and death due to other cardiovascular causes, as 
follows: 
 
1. Death Due to Acute MI refers to a death by any mechanism (arrhythmia, heart failure 
[HF], low output) within 30 days after a MI related to the immediate consequences of 
the myocardial infarction, such as progressive congestive heart failure (CHF), 
inadequate cardiac output, or recalcitrant arrhythmia. If these events occur after a 
“break” (e.g., a CHF- and arrhythmia-free period of at least a week), they should be 
designated by the immediate cause, even though the MI may have increased the risk of 
that event (e.g., late arrhythmic death becomes more likely after an acute MI). The 
acute MI should be verified to the extent possible by the diagnostic criteria outlined 
for acute MI or by autopsy findings showing recent MI or recent coronary thrombus. 
Sudden cardiac death, if accompanied by symptoms suggestive of myocardial ischemia, 
new ST elevation, new left bundle branch block ( LBBB), or evidence of fresh thrombus 
by coronary angiography and/or at autopsy should be considered death resulting from an 
acute MI, even if death occurs before blood samples or 12-lead electrocardiogram (ECG) 
could be obtained, or at a time before the appearance of cardiac biomarkers in the blood. 
Death resulting from a procedure to treat a MI (percutaneous coronary intervention 
[PCI], coronary artery bypass graft surgery [CABG]), or to treat a complication resulting 
from MI, should also be considered death due to acute MI. 
 
Death resulting from a procedure to treat myocardial ischemia (angina) or death due to 
a MI that occurs as a direct consequence of a cardiovascular 
investigation/procedure/operation should be considered as a death due to other 
cardiovascular causes. 
 
2. Sudden Cardiac Death refers to a death that occurs unexpectedly, not following an 
acute MI, and includes the following deaths: 
a. Death witnessed and instantaneous without new or worsening symptoms 
b. Death witnessed within 60 minutes of the onset of new or worsening cardiac 
symptoms, unless the symptoms suggest acute MI 
c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an 
ECG recording, witnessed on a monitor, or unwitnessed but found on implantable 
cardioverter-defibrillator review) 
d. Death after unsuccessful resuscitation from cardiac arrest 
e. Death after successful resuscitation from cardiac arrest and without identification of 
a noncardiac etiology (postcardiac arrest syndrome) 
f. Unwitnessed death without other cause of death (information regarding the 
patient’s clinical status preceding death should be provided, if available) 
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General Considerations 
 A subject seen alive and clinically stable 12-24 hours prior to being found dead 
without any evidence or information of a specific cause of death should be classified 
as “sudden cardiac death.” Typical scenarios include: 
− Subject well the previous day but found dead in bed the next day 
− Subject found dead at home on the couch with the television on 
 Deaths for which there is no information beyond “Patient found dead at home” may 
be classified as “death due to other cardiovascular causes” or in some trials, 
“undetermined cause of death.” Please see Definition of Undetermined Cause of Death, 
for full details. 
 
3. Death Due to HF or Cardiogenic Shock refers to a death occurring in the context of 
clinically worsening symptoms and/or signs of heart failure without evidence of another 
cause of death and not following an acute MI. Note that deaths due to HF can have 
various etiologies, including one or more acute MIs (late effect), ischemic or 
nonischemic cardiomyopathy, or valve disease. 
 
Death due to HF or Cardiogenic Shock should include sudden death occurring during 
an admission for worsening heart failure as well as death from progressive HF or 
cardiogenic shock following implantation of a mechanical-assist device. 
 
New or worsening signs and/or symptoms of CHF include any of the following: 
a. New or increasing symptoms and/or signs of HF requiring the initiation of, or an 
increase in, treatment directed at HF or occurring in a patient already receiving 
maximal therapy for HF 
b. HF symptoms or signs requiring continuous intravenous therapy or chronic oxygen 
administration for hypoxia due to pulmonary edema 
c. Confinement to bed predominantly due to HF symptoms 
d. Pulmonary edema sufficient to cause tachypnea and distress not occurring in the 
context of an acute MI, worsening renal function, or as the consequence of an 
arrhythmia occurring in the absence of worsening heart failure 
e. Cardiogenic shock not occurring in the context of an acute MI or as the consequence 
of an arrhythmia occurring in the absence of worsening HF 
 
Cardiogenic shock is defined as systolic blood pressure (SBP) <90 mmHg for greater 
than 1 hour, not responsive to fluid resuscitation and/or heart rate correction, and felt to 
be secondary to cardiac dysfunction and associated with at least one of the following 
signs of hypoperfusion: 
 Cool, clammy skin or 
 Oliguria (urine output <30 ml/hour) or 
 Altered sensorium or 
 Cardiac index <2.2 l/min/m
2
 
Cardiogenic shock can also be defined if SBP <90 mmHg and increases to ≥90 
mmHg in less than 1 hour with positive inotropic or vasopressor agents alone and/or 
with mechanical support. 
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General Considerations 
HF may have a number of underlying causes, including acute or chronic ischemia, 
structural heart disease (e.g., hypertrophic cardiomyopathy), and valvular heart disease. 
Where treatments are likely to have specific effects, and it is likely to be possible to 
distinguish between the various causes, then it may be reasonable to separate out the 
relevant treatment effects. For example, obesity drugs such as fenfluramine (pondimin) 
and dexfenfluramine (redux) were found to be associated with the development of 
valvular heart disease and pulmonary hypertension. In other cases, the aggregation implied 
by the definition above may be more appropriate. 
 
4. Death Due to Stroke refers to death occurring up to 30 days after a stroke that is either due 
to the stroke or caused by a complication of the stroke. 
 
5. Death Due to Other Cardiovascular Causes refers to a cardiovascular death not included 
in the above categories (e.g., dysrhythmia unrelated to sudden cardiac death, pulmonary 
embolism, cardiovascular intervention [other than one related to an acute MI], aortic 
aneurysm rupture, or peripheral arterial disease). Mortal complications of cardiac surgery 
or nonsurgical revascularization should be classified as cardiovascular deaths. 
 
Hospitalized Congestive Heart Failure 
HF requiring hospitalization is defined as an event that meets the following criteria: 
1. Requires hospitalization defined as an admission to an inpatient unit or a visit to an 
emergency department that results in at least a 24-hour stay (or a date change if the time 
of admission/discharge is not available). 
AND 
2. Clinical symptoms of HF, including ≥1 of the following new or 
worsening conditions: 
 Dyspnea 
 Orthopnea 
 Paroxysmal nocturnal dyspnea 
 Increasing fatigue/worsening exercise tolerance 
AND 
3. Physical signs of HF, including ≥2 of the following: 
 Edema (greater than 2+ lower extremity) 
 Pulmonary crackles greater than basilar (pulmonary edema must be sufficient to 
cause tachypnea and distress not occurring in the context of an acute MI or as the 
consequence of an arrhythmia occurring in the absence of worsening HF) 
 Jugular venous distension 
 Tachypnea (respiratory rate >20 breaths/minute) 
 Rapid weight gain 
 S3 gallop 
 Increasing abdominal distension or ascites 
 Hepatojugular reflux 
 Radiological evidence of worsening HF 
 A right heart catheterization within 24 hours of admission showing a pulmonary 
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capillary wedge pressure (pulmonary artery occlusion pressure) ≥18 mmHg or a 
cardiac output <2.2 l/min/m
2
 
 
Note: biomarker results (e.g., brain natriuretic peptide [BNP]) consistent with CHF will 
be supportive of this diagnosis, but the elevation in BNP cannot be due to other 
conditions such as cor pulmonale, pulmonary embolus, primary pulmonary hypertension, 
or congenital heart disease. Increasing levels of BNP, although not exceeding the ULN, 
may also be supportive of the diagnosis of CHF in selected cases (e.g., morbid obesity). 
AND 
4. Need for additional/increased therapy 
 Initiation of, or an increase in, treatment directed at HF or occurring in a patient 
already receiving maximal therapy for HF and including ≥1 of the following: 
 Initiation of or a significant augmentation in oral therapy for the treatment of CHF 
 Initiation of intravenous diuretic, inotrope, or vasodilator therapy 
 Up-titration of intravenous therapy, if already on therapy 
 Initiation of mechanical or surgical intervention (mechanical circulatory 
support, heart transplantation or ventricular pacing to improve cardiac function), or 
the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at 
treatment of HF. 
AND 
5. No other noncardiac etiology (such as chronic obstructive pulmonary disease, hepatic 
cirrhosis, acute renal failure, or venous insufficiency) and no other cardiac etiology (such 
as pulmonary embolus, cor pulmonale, primary pulmonary hypertension, or congenital 
heart disease) for signs or symptoms is identified. 
 
Note: it is recognized that some patients may have multiple simultaneous disease processes. 
Nevertheless, for the endpoint event of HF requiring hospitalization, the diagnosis of CHF 
would need to be the primary disease process accounting for the above signs and 
symptoms. 
 
